
TARA Stock Forecast & Price Target
TARA Analyst Ratings
Bulls say
Protara Therapeutics Inc. has demonstrated a robust efficacy profile for its therapy TARA-002, with a notable 100% durability and an 80% salvage rate upon re-induction observed at the 6-month mark, surpassing earlier results at 3 months. The positive outcomes from Ph2 trials for the intravenous choline chloride therapy indicate significant improvements in liver health, with radiographic assessments revealing enhanced management of liver steatosis compared to placebo. These developments, alongside TARA-002's strong safety profile and potential competitive advantages in the non-muscle invasive bladder cancer (NMIBC) landscape, position Protara Therapeutics favorably for future adoption and market success.
Bears say
Protara Therapeutics Inc reported a substantial net loss of $12.7 million, translating to ($0.48) per share in the fourth quarter of 2024, highlighting ongoing financial challenges. Despite promising early results for its TARA-002 program in non-muscle invasive bladder cancer (NMIBC), the company's stock is trading at a significant discount compared to peers, which may indicate investor skepticism about its long-term viability and market positioning. Furthermore, the competitive landscape for NMIBC creates additional pressure, particularly as current treatments like ANKTIVA face supply constraints, potentially hindering Protara's growth.
This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TARA Analyst Forecast & Price Prediction
Start investing in TARA
Order type
Buy in
Order amount
Est. shares
0 shares